

OCT 31 2007

AMENDMENT TO THE CLAIMS

Please amend the claims as follows, without prejudice or disclaimer. This listing of the claims replaces any prior listings of the claims.

1. (Currently amended) A method for treating ~~cancer~~ melanoma comprising:
 - a) administering to a host a composition containing a ~~tumor antigen, fragment thereof or~~ nucleic acid encoding ~~the~~ a tumor antigen such that the host develops an immune response against the tumor antigen; and,
 - b) subsequently administering a therapeutically effective amount of interferon to the host ~~a high dose of a cytokine~~;whereby the combination of steps a) and b) provides an enhanced T cell response in the host relative to that which occurs following step a) alone.
2. (Cancelled) *The method of claim 1 wherein the tumor antigen is administered as a polypeptide or peptide.*
3. (Cancelled) *The method of claim 1 wherein the composition comprises a nucleic acid encoding a tumor antigen.*
4. (Currently Amended) The method of claim ~~3~~ 1 wherein the nucleic acid is contained within a plasmid or a viral vector.
5. (Original) The method of claim 4 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.
6. (Original) The method of claim 5 wherein the viral vector is a poxvirus selected from the group consisting of vaccinia, NYVAC, MVA, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
7. (Original) The method of claim 6 wherein the viral vector is a poxvirus selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
8. (Original) The method of claim 1 wherein the cytokine is IFN.
9. (Original) The method of claim 8 wherein the cytokine is IFN- α .
10. (Original) The method of claim 9 wherein the cytokine is IFN- α 2b.
11. (Original) The method of claim 1 wherein the tumor antigen is selected from the group consisting of gp100, MART-1/Melan A, gp75/TRP-1, tyrosinase, NY-ESO-1,

- melanoma proteoglycan, a MAGE antigen, a BAGE antigen, a GAGE antigen, RAGE antigen, N-acetylglucosaminyltransferase-V, p15, β -catenin, MUM-1, cyclin dependent kinase-4, p21-ras, BCR-abl, p53, p185 HER2/neu, epidermal growth factor receptor, carcinoembryonic antigen, modified carcinoembryonic antigen, carcinoma-associated mutated mucins, an Epstein Barr Virus EBNA gene product, papilloma virus E7, papilloma virus E6, prostate specific antigen, prostate specific membrane antigen, KSA, kinesin 2, HIP-55, TGF β -1 anti-apoptotic factor, tumor protein D52, H1F1, an NY-BR antigen, fragments thereof, and derivatives thereof.
12. (Original) The method of claim 11 wherein the tumor antigen is selected from the group consisting of gp100, MAGE-1, MAGE-2, MAGE-3, MAGE-4, MAGE-6, MAGE-12, MAGE-51, GAGE-1, GAGE-2, RAGE-1, NY-BR-1, NY-BR-62, NY-BR-75, NY-BR-85, NY-BRP-87, and NY-BR-96.
13. (Original) The method of claim 12 wherein the tumor antigen is gp100.
14. (Currently amended) The method of claim 1 wherein the composition comprises an poxviral vector encoding a tumor antigen or a fragment thereof and the cytokine is a T cell activating cytokine.
15. (Original) The method of claim 14 wherein poxviral vector is an ALVAC vector and the T cell activating cytokine is IFN.
16. (Original) The method of claim 15 wherein the T cell activating cytokine is IFN α .
17. (Original) The method of claim 16 wherein the T cell activating cytokine is IFN α 2b.
18. (Original) The method of claim 17 wherein IFN α 2b is administered at at least 10 MU/m²/d IV at least two times per week for at least two weeks.
19. (Original) The method of claim 18 wherein IFN α 2b is administered at at least 10 MU/m²/d IV at least three times per week for at least two weeks.
20. (Original) The method of claim 19 wherein IFN α 2b is administered at at least 10 MU/m²/d IV at least four times per week for at least two weeks.
21. (Original) The method of claim 20 wherein IFN α 2b is administered at at least 10 MU/m²/d IV at least five times per week for at least two weeks.
22. (Original) The method of claim 21 wherein IFN α 2b is administered at at least 20 MU/m²/d IV at least five times per week for at least four weeks.